Oragenics, Inc. (OGEN)
| Market Cap | 3.52M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -19.97M |
| Shares Out | 12.21M |
| EPS (ttm) | -4.66 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 174,019 |
| Open | 0.291 |
| Previous Close | 0.280 |
| Day's Range | 0.281 - 0.294 |
| 52-Week Range | 0.250 - 7.740 |
| Beta | 0.48 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 13, 2024 |
About OGEN
Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The company also develops NT-CoV2-1, a SARS-CoV-2 vaccine product candidate; and Lantibioti... [Read more]
Financial Performance
In 2023, Oragenics's revenue was $37,653, a decrease of -71.37% compared to the previous year's $131,521. Losses were -$20.66 million, 44.6% more than in 2022.
Financial StatementsNews
Oragenics, Inc. to Present at The Centurion One Capital 2nd Annual Bahamas Summit
SARASOTA, Fla., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Oragenics Inc. (NYSE American: OGEN), a company focused on developing new treatments for brain-related health conditions, announced it will be present...
Oragenics, Inc. Updates Shareholders on Concussion Drug Progress and Phase II Trial Preparation
SARASOTA, Fla., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biopharmaceutical company committed to developing novel therapies for neurological disorders, today provided ...
Oragenics Inc. Successfully Completes Key FDA-Recognized Study for ONP-002
SARASOTA, Fla., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Oragenics Inc. (NYSE American: OGEN), a company focused on developing new treatments for brain-related health conditions, has completed a key study fo...
Oragenics, Inc. Announces Closing of Public Offering
SARASOTA, Fla., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders...
Oragenics, Inc. Announces Pricing of Public Offering
SARASOTA, Fla., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders...
Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients
• Falls and car accidents lead incidence of concussions in emergency departments • Spray-dried drug formulation allows for easy delivery to patients • No pharmaceutical treatment is available for conc...
Oragenics, Inc. Provides Update on its Drug Intended to Treat Concussion and Non-Compliance with NYSE American Continued Listing Standards
SARASOTA, Fla., Aug. 16, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN) ("the Company"), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurolo...
Oragenics Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature Range
• ONP-002 stability eliminates need for cumbersome cold storage • No FDA-approved pharmaceutical treatment available for concussion
Oragenics, Inc. Announces Concussion Drug Successfully Completes FDA-Required Genotoxicity Study
– ONP-002 showed no cancer-causing DNA damage – Phase II clinical trial being planned SARASOTA, Fla., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on deve...
Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing
The potential addressable market opportunity for ONP-002 includes an estimated 69 million concussions globally The potential addressable market opportunity for ONP-002 includes an estimated 69 million...
Oragenics Develops Automated Intranasal Device for Treating Concussed Patients
SARASOTA, Fla., June 27, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders,...
Oragenics, Inc. Announces Proposed Public Offering
SARASOTA, Fla., June 24, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE: OGEN) (“Oragenics” or the “Company”), a company focused on developing unique, intranasal pharmaceuticals for the treatment of n...
Oragenics Appoints William “Frank” Peacock MD as Chief Clinical Officer
Dr. Peacock to Oversee Upcoming Phase II Clinical Trial for Treating Concussion in the Emergency Department Dr. Peacock to Oversee Upcoming Phase II Clinical Trial for Treating Concussion in the Emerg...
Oragenics, Inc. to Host Webinar Panel on Neurotrauma Medicine
SARASOTA, Fla., May 17, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a pioneering pharmaceutical company specializing in intranasal treatments for neurological disorders, today anno...
Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards
SARASOTA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced ...
Oragenics, Inc. Files 10K and Provides Company Update
SARASOTA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (the “Company”) (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, ...
Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion
SARASOTA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced ...
Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion
SARASOTA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced ...
Oragenics Announces Closing of Public Offering
SARASOTA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a company focused on developing unique, intranasal nanoparticle pharmaceuticals for the treatment...
Oragenics Announces Pricing of Public Offering
SARASOTA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a company focused on developing unique, intranasal nanoparticle pharmaceuticals for the treatment...
Oragenics Announces Proposed Public Offering
SARASOTA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a company focused on developing unique, intranasal nanoparticle pharmaceuticals for the treatment...
Oragenics, Inc. Announces Leadership Transition
SARASOTA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (the “Company”), a company focused on developing unique, intranasal nanoparticle pharmaceuticals for the treatment of neurologica...
Oragenics, Inc. Announces Expiration of Its Investment Banking Engagement Agreement
SARASOTA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal nanoparticle pharmaceuticals for the treatment of neurological disorders, tod...
Oragenics, Inc. Preparing for Phase II Clinical Trials to Treat Concussion
SARASOTA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal nanoparticle pharmaceuticals for the treatment of neurological disorders, tod...
Oragenics Announces Termination of At-The-Market Offering Program
TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) today announced it has terminated its previously announced “at-the-market” (“ATM”) equity offering pr...